Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Article Title: NOSTRIN is an emerging negative regulator of decompensated cirrhotic patients with portal hypertension.
doi: 10.1016/j.dld.2024.08.050
Figure Lengend Snippet: Fig. 3. (A, i) Pathological changes observed by H&E of human cirrhotic liver and control liver sections (magnification - 10X). The cirrhotic patient’s liver showed increased Nostrin expression and decreased peNOS expression, which was concomitant with reduced NO bioavailability. Representative images (magnification - 20X) of human cirrhotic liver tissue sections showing elevated hepatic Nostrin levels by DAB immunohistochemistry (A, ii). Representative images (magnification - 20X) of human liver tissue sections showing elevated hepatic eNOS levels in the control liver compared to the cirrhotic liver by DAB immunohistochemistry A, iii). Hepatic Nostrin protein expression by immunoblot assay with densitometry quantification (B) and mRNA expression by qPCR (C). Liver total eNOS and p-eNOS expression were evaluated by immunoblot assay with densitometry quantification (D). Hepatic total and phosphorylated eNOS/eNOS in the serine 1177 residue (peNOS) expression by immunoblot assay with densitometry quantification (D) and mRNA expression by qPCR (E). The hepatic cGMP levels were measured by ELISA (F). Data are expressed as mean ± standard error of mean (SEM). Symbols represent ∗p < 0.05; ∗∗p < 0.01 compared to control liver. β-actin was used as an internal loading control.
Article Snippet: Tissues were incubated with 5 % goat s t s ( t o r a H m ( t c s 2 f a a u R t e R A i ( A a w r i P t m 2 t p ( s t ( p R a t ( t i w i a ( H t a 2 t s a s S t l ( P 3 3 a c w t i t s p o B 3 a a erum for 1 hr and incubated overnight at 4 °C with primary anibodies against rabbit polyclonal anti-human Nostrin (1:100; cat: c-134,803, Santacruz) and rabbit polyclonal anti- human eNOS 1:100; cat: PA-1712–1, Bosterbio).
Techniques: Control, Expressing, Immunohistochemistry, Western Blot, Residue, Enzyme-linked Immunosorbent Assay